Zometa zoledronic acid regulatory update

Novartis disclosed in its 3Q10 earnings that FDA extended the PDUFA date for an sNDA for Zometa zoledronic acid for the adjuvant treatment of early breast cancer in premenopausal women to 1Q11 from 4Q...